BIOSTATISTICS / BIOINFORMATICS SHARED RESOURCE (Core-667) ABSTRACT Overview: The University of Colorado Cancer Center (UCCC) Biostatistics and Bioinformatics Shared Resource (BBSR) provides biostatistical and bioinformatics leadership and analytic support for laboratory- based cancer research, experimental therapeutic studies and clinical trials, as well as population-based studies (e.g., epidemiological, health outcomes and disparities research in our catchment area), to UCCC members. Expertise: Substantial expertise is available for the analysis of clinical trials, statistical genetics, next- generation sequencing, predictive modeling, cancer-focused bioinformatics, and health services research. Services: BBSR support of UCCC members begins with study design to address research questions, along with sample size determination and analytical plans, as needed for grant and clinical trial development and protocol submission. BBSR support also includes data and safety monitoring of clinical trials analysis, and assistance with manuscript preparation in relation to data interpretation and scientific conclusions. The BBSR actively participates in the Protocol Review and Monitoring System (PRMS) and Data and Safety Monitoring Committees (DSMC). The BBSR collaborates with other UCCC Shared Resources (particularly Genomics and the Molecular Pathology Shared Resources) in research studies and the development of new bioinformatic pipelines. Consultation and Education: Faculty biostatisticians and bioinformaticists also provide educational opportunities, through one-on-one training in biostatistics and bioinformatics, and are engaged in consultation with investigators and in the development of novel methods and tools that directly enhance UCCC member research. Management: The BBSR is comprised of two distinct components ? biostatistics and bioinformatics. Biostatistics is a UCCC Shared Resource while bioinformatics is an institutional core. Both are managed by UCCC; and both are overseen by the Associate Director for Population Sciences. Use of Services: Since July 2011, 252 investigators have used BBSR services. Sixty-seven percent of users (169) were UCCC members, representing all 6 Programs and resulting in 112 peer-reviewed publications. CCSG funding represents 25% of the annual operating budget. The remaining support comes from institutional support (43%), the CCTSI (4%) and user fees (28%). Future Directions: In the next 5 years, the BBSR will increase bioinformatics staff to accommodate the predicted growth of research projects that generate high-dimensional data. Future hires in bioinformatics will leverage resources with the newly-formed Division of Biomedical Informatics and Personalized Medicine (BIPM). Biostatistics staff hires will also be needed to accommodate planned growth in Population Sciences and clinical research including trials. Supporting the initiatives that form the Future Directions in the Director's Overview, the BBSR anticipates playing an important role in the Overcoming Resistance to Targeted Agents, the Promoting Healthy Living Initiative and the Front Range Clinical Trials Network, the latter requiring biostatistical expertise in multisite cancer clinical trial design.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-29
Application #
9207576
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
29
Fiscal Year
2017
Total Cost
$254,305
Indirect Cost
$90,765
Name
University of Colorado Denver
Department
Type
Domestic Higher Education
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ryan, Weston Kenneth; Fernandez, Josiah; Peterson, Mikayla Katherine et al. (2018) Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase. Cell Death Differ :
Monks, Jenifer; Orlicky, David J; Stefanski, Adrianne L et al. (2018) Maternal obesity during lactation may protect offspring from high fat diet-induced metabolic dysfunction. Nutr Diabetes 8:18
Garcia, Tamara B; Fosmire, Susan P; Porter, Christopher C (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30-33
Wahdan-Alaswad, R S; Edgerton, S M; Salem, H S et al. (2018) Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res 4:
Oweida, Ayman; Phan, Andy; Vancourt, Benjamin et al. (2018) Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 28:739-747
Gadalla, Shahinaz M; Wang, Tao; Loftus, David et al. (2018) No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 53:383-391

Showing the most recent 10 out of 1634 publications